{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:51:12Z","timestamp":1790653872863,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1TR004909"],"award-info":[{"award-number":["UM1TR004909"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR003107"],"award-info":[{"award-number":["UL1TR003107"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020523","name":"United States Drug Enforcement Administration","doi-asserted-by":"publisher","award":["15DDHQ20N00000008"],"award-info":[{"award-number":["15DDHQ20N00000008"]}],"id":[{"id":"10.13039\/100020523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020523","name":"United States Drug Enforcement Administration","doi-asserted-by":"publisher","award":["15DDHQ24A00000020"],"award-info":[{"award-number":["15DDHQ24A00000020"]}],"id":[{"id":"10.13039\/100020523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA022981"],"award-info":[{"award-number":["T32 DA022981"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpet.2026.104988","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:19:25Z","timestamp":1784301565000},"page":"104988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interoceptive effects of N1-substituted lysergamides in rats: Role of agonist affinity at 5-hydroxytryptamine receptors and in vivo metabolism to lysergic acid diethylamide"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2696-4524","authenticated-orcid":false,"given":"Michael D.","family":"Berquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Gannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-5712","authenticated-orcid":false,"given":"Kevin M.","family":"Honeywell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1600-2894","authenticated-orcid":false,"given":"Hannah E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6029-7078","authenticated-orcid":false,"given":"Theresa M.","family":"Carbonaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-2046","authenticated-orcid":false,"given":"Laura A.","family":"Kozell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atheir I.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-8845","authenticated-orcid":false,"given":"William E.","family":"Schutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4868-8913","authenticated-orcid":false,"given":"Marina","family":"Avram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-1593","authenticated-orcid":false,"given":"William E.","family":"Fantegrossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jpet.2026.104988_bib1","doi-asserted-by":"crossref","first-page":"11027","DOI":"10.1021\/acs.jmedchem.3c01178","article-title":"2B determined: the future of the serotonin receptor 2B in drug discovery","volume":"66","author":"Bender","year":"2023","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.jpet.2026.104988_bib2","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/add.15987","article-title":"Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP","volume":"117","author":"Livne","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jpet.2026.104988_bib3","article-title":"Use of plant-based hallucinogens and dissociative agents: U.S. time trends, 2002-2019","volume":"16","author":"Walsh","year":"2022","journal-title":"Addict Behav Rep"},{"issue":"7","key":"10.1016\/j.jpet.2026.104988_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.7326\/ANNALS-24-03145","article-title":"The rise of psilocybin use in the United States: a multisource observational study","volume":"178","author":"Rockhill","year":"2025","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jpet.2026.104988_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43453","article-title":"Trends in hallucinogen-related emergency department and hospital admissions, 2016 to 2023","volume":"8","author":"Steinle","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/psymed.2023.0027","article-title":"Perceived risk of trying lysergic acid diethylamide in the United States from 2015 to 2019: are Americans assessing lysergic acid diethylamide's risk profile more favorably?","volume":"2","author":"Barnett","year":"2024","journal-title":"Psychedelic Med (New Rochelle)"},{"issue":"6","key":"10.1016\/j.jpet.2026.104988_bib7","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00213-022-06142-4","article-title":"The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides","volume":"239","author":"Mallaroni","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"2 Suppl","key":"10.1016\/j.jpet.2026.104988_bib9","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1038\/sj.npp.1395318","article-title":"Serotonin and hallucinogens","volume":"21","author":"Aghajanian","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.jpet.2026.104988_bib11","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jpet.2026.104988_bib12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/dta.1884","article-title":"Return of the lysergamides. Part I: analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)","volume":"8","author":"Brandt","year":"2016","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.jpet.2026.104988_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107856","article-title":"Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)","volume":"172","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.jpet.2026.104988_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/dta.1985","article-title":"Return of the lysergamides. Part II: analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)","volume":"9","author":"Brandt","year":"2017","journal-title":"Drug Test Anal"},{"issue":"19","key":"10.1016\/j.jpet.2026.104988_bib15","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1021\/jm020153s","article-title":"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)","volume":"45","author":"Nichols","year":"2002","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009019","article-title":"Psychedelics and the human receptorome","volume":"5","author":"Ray","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jpet.2026.104988_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/1556-4029.14268","article-title":"Prodrugs of new psychoactive substances (NPS): a new challenge","volume":"65","author":"Elliott","year":"2020","journal-title":"J Forensic Sci"},{"issue":"19","key":"10.1016\/j.jpet.2026.104988_bib18","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1007\/s00216-018-1558-9","article-title":"In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures","volume":"411","author":"Wagmann","year":"2019","journal-title":"Anal Bioanal Chem"},{"issue":"8","key":"10.1016\/j.jpet.2026.104988_bib19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/dta.2821","article-title":"Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration","volume":"12","author":"Grumann","year":"2020","journal-title":"Drug Test Anal"},{"issue":"5","key":"10.1016\/j.jpet.2026.104988_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00213-013-3303-6","article-title":"Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function","volume":"231","author":"Eshleman","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2026.104988_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcp.2018.09.024","article-title":"Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors","volume":"158","author":"Eshleman","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104988_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.111.179705","article-title":"Abuse liability profile of three substituted tryptamines","volume":"338","author":"Gatch","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104988_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/jpet.116.239376","article-title":"Individual differences in the relative reinforcing effects of 3,4-Methylenedioxypyrovalerone under fixed and progressive ratio schedules of reinforcement in rats","volume":"361","author":"Gannon","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.jpet.2026.104988_bib24","first-page":"1584","article-title":"Hands-free analytical urine testing technology validated for drug-facilitated crime investigations","volume":"36","author":"Avram","year":"2023","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00213-005-0068-6","article-title":"The 5-HT1A receptor and the stimulus effects of LSD in the rat","volume":"182","author":"Reissig","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/dta.2222","article-title":"Return of the lysergamides. Part IV: analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)","volume":"10","author":"Brandt","year":"2018","journal-title":"Drug Test Anal"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib27","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2025.10974","article-title":"Trends in the psychedelic renaissance: applying artificial intelligence to measure media portrayal of psychedelic drugs in the 21st century","volume":"12","author":"Bender","year":"2026","journal-title":"BJPsych Open"},{"issue":"3","key":"10.1016\/j.jpet.2026.104988_bib28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14740330902931524","article-title":"Serotonergic drugs and valvular heart disease","volume":"8","author":"Rothman","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.jpet.2026.104988_bib29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/15680266113139990039","article-title":"Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease","volume":"13","author":"Reid","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jpet.2026.104988_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.1998.tb10180.x","article-title":"Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists","volume":"861","author":"Berg","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"19","key":"10.1016\/j.jpet.2026.104988_bib31","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1021\/acschemneuro.5c00647","article-title":"Serotonin 5-HT2C receptor signaling analysis reveals psychedelic biased agonism","volume":"16","author":"Bonniwell","year":"2025","journal-title":"ACS Chem Neurosci"},{"issue":"2 Suppl","key":"10.1016\/j.jpet.2026.104988_bib32","first-page":"77S","article-title":"Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD)","volume":"21","author":"Backstrom","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11419-023-00661-1","article-title":"Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products","volume":"41","author":"Tanaka","year":"2023","journal-title":"Forensic Toxicol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104988_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11419-025-00718-3","article-title":"Identification of two lysergic acid diethylamide analogs, 1-(3-(trimethylsilyl) propionyl) lysergic acid diethylamide (1S-LSD) and 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD), in paper sheet products distributed on the internet","volume":"43","author":"Tanaka","year":"2025","journal-title":"Forensic Toxicol"},{"issue":"4","key":"10.1016\/j.jpet.2026.104988_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/dta.70039","volume":"18","author":"Tanaka","year":"2026","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.jpet.2026.104988_bib36","series-title":"Biochemistry","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.102350","article-title":"Hydrolases: the most diverse class of enzymes","author":"Shukla","year":"2022"},{"issue":"9","key":"10.1016\/j.jpet.2026.104988_bib37","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/biom14091125","article-title":"CYP3A-mediated carbon-carbon bond cleavages in drug metabolism","volume":"14","author":"Zhou","year":"2024","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.jpet.2026.104988_bib38","first-page":"1061","article-title":"Decreases of brain serotonin following a food restriction schedule of 4 weeks in male and female rats","volume":"6","author":"Haider","year":"2000","journal-title":"Med Sci Monit"},{"issue":"6","key":"10.1016\/j.jpet.2026.104988_bib39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00001756-199604260-00011","article-title":"Food restriction decreases serotonin and its synthesis rate in the hypothalamus","volume":"7","author":"Haleem","year":"1996","journal-title":"Neuroreport"},{"issue":"12","key":"10.1016\/j.jpet.2026.104988_bib40","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0006-3223(96)00265-X","article-title":"Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex","volume":"41","author":"Huether","year":"1997","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2026.104988_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/1028415031000115936","article-title":"The differential effects of food restriction on 5-HT1A and 5-HT1B receptor mediated control of serotonergic transmission in the hippocampus and hypothalamus of rats","volume":"6","author":"Gur","year":"2003","journal-title":"Nutr Neurosci"},{"issue":"4","key":"10.1016\/j.jpet.2026.104988_bib42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/FBP.0b013e328308f1d6","article-title":"Food restriction and streptozotocin treatment decrease 5-HT1A and 5-HT2A receptor-mediated behavioral effects in rats","volume":"19","author":"Li","year":"2008","journal-title":"Behav Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T20:02:38Z","timestamp":1787515358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"alternative-id":["S0022356526011882"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104988","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interoceptive effects of N1-substituted lysergamides in rats: Role of agonist affinity at 5-hydroxytryptamine receptors and in vivo metabolism to lysergic acid diethylamide","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"104988"}}